RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis
Europe - FRA:RHK - DE0007042301 - Common Stock
12 EUR
-0.1 (-0.83%)
RHK gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 27 industry peers in the Health Care Providers & Services industry. RHK is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RHK is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RHK was profitable.
In the past year RHK had a positive cash flow from operations.
RHK had positive earnings in each of the past 5 years.
Each year in the past 5 years RHK had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of 2.02%, RHK perfoms like the industry average, outperforming 44.44% of the companies in the same industry.
RHK has a worse Return On Equity (2.90%) than 62.96% of its industry peers.
RHK has a worse Return On Invested Capital (2.67%) than 66.67% of its industry peers.
The Average Return On Invested Capital over the past 3 years for RHK is below the industry average of 6.04%.
The last Return On Invested Capital (2.67%) for RHK is above the 3 year average (2.34%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROIC | 2.67% |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
1.3 Margins
The Profit Margin of RHK (2.28%) is comparable to the rest of the industry.
RHK's Profit Margin has declined in the last couple of years.
The Operating Margin of RHK (2.86%) is worse than 66.67% of its industry peers.
In the last couple of years the Operating Margin of RHK has declined.
With a decent Gross Margin value of 66.81%, RHK is doing good in the industry, outperforming 70.37% of the companies in the same industry.
In the last couple of years the Gross Margin of RHK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% |
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RHK is destroying value.
RHK has about the same amout of shares outstanding than it did 1 year ago.
RHK has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for RHK has been reduced compared to a year ago.
2.2 Solvency
RHK has an Altman-Z score of 3.02. This indicates that RHK is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.02, RHK belongs to the top of the industry, outperforming 81.48% of the companies in the same industry.
RHK has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.09, RHK belongs to the best of the industry, outperforming 96.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.02 |
ROIC/WACC0.41
WACC6.46%
2.3 Liquidity
RHK has a Current Ratio of 2.28. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
RHK has a better Current ratio (2.28) than 92.59% of its industry peers.
A Quick Ratio of 2.19 indicates that RHK has no problem at all paying its short term obligations.
RHK has a Quick ratio of 2.19. This is amongst the best in the industry. RHK outperforms 92.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 |
3. Growth
3.1 Past
The earnings per share for RHK have decreased strongly by -19.59% in the last year.
RHK shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.03% yearly.
Looking at the last year, RHK shows a quite strong growth in Revenue. The Revenue has grown by 9.41% in the last year.
The Revenue has been growing slightly by 4.12% on average over the past years.
EPS 1Y (TTM)-19.59%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%-28.57%
Revenue 1Y (TTM)9.41%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%6.64%
3.2 Future
Based on estimates for the next years, RHK will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.47% on average per year.
The Revenue is expected to grow by 5.84% on average over the next years.
EPS Next Y9.14%
EPS Next 2Y10.96%
EPS Next 3Y11.09%
EPS Next 5Y11.47%
Revenue Next Year5.98%
Revenue Next 2Y4.97%
Revenue Next 3Y6.5%
Revenue Next 5Y5.84%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 21.43, the valuation of RHK can be described as rather expensive.
RHK's Price/Earnings ratio is in line with the industry average.
RHK's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.67.
A Price/Forward Earnings ratio of 15.56 indicates a correct valuation of RHK.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RHK is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of RHK to the average of the S&P500 Index (31.86), we can say RHK is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.43 | ||
| Fwd PE | 15.56 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -0.11 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RHK does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)2.34
PEG (5Y)630.14
EPS Next 2Y10.96%
EPS Next 3Y11.09%
5. Dividend
5.1 Amount
With a yearly dividend of 0.83%, RHK is not a good candidate for dividend investing.
RHK's Dividend Yield is comparable with the industry average which is at 2.55.
With a Dividend Yield of 0.83, RHK pays less dividend than the S&P500 average, which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.83% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
17.78% of the earnings are spent on dividend by RHK. This is a low number and sustainable payout ratio.
DP17.78%
EPS Next 2Y10.96%
EPS Next 3Y11.09%
FRA:RHK (11/6/2025, 7:00:00 PM)
12
-0.1 (-0.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap803.52M
Revenue(TTM)1.65B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (20.42%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.83% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.97%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.43 | ||
| Fwd PE | 15.56 | ||
| P/S | 0.49 | ||
| P/FCF | N/A | ||
| P/OCF | 13.02 | ||
| P/B | 0.62 | ||
| P/tB | 0.71 | ||
| EV/EBITDA | -0.11 |
EPS(TTM)0.56
EY4.67%
EPS(NY)0.77
Fwd EY6.42%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.68%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)2.34
PEG (5Y)630.14
Graham Number15.64
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROCE | 3.25% | ||
| ROIC | 2.67% | ||
| ROICexc | 4.45% | ||
| ROICexgc | 5.55% | ||
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% | ||
| FCFM | N/A |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.07 | ||
| Cap/Depr | 112.99% | ||
| Cap/Sales | 4.21% | ||
| Interest Coverage | 14.78 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 | ||
| Altman-Z | 3.02 |
F-Score6
WACC6.46%
ROIC/WACC0.41
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-19.59%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%-28.57%
EPS Next Y9.14%
EPS Next 2Y10.96%
EPS Next 3Y11.09%
EPS Next 5Y11.47%
Revenue 1Y (TTM)9.41%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%6.64%
Revenue Next Year5.98%
Revenue Next 2Y4.97%
Revenue Next 3Y6.5%
Revenue Next 5Y5.84%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y27.85%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%
RHOEN-KLINIKUM AG / RHK.DE FAQ
Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?
ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.
What is the valuation status for RHK stock?
ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.
What is the profitability of RHK stock?
RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.
What is the valuation of RHOEN-KLINIKUM AG based on its PE and PB ratios?
The Price/Earnings (PE) ratio for RHOEN-KLINIKUM AG (RHK.DE) is 21.43 and the Price/Book (PB) ratio is 0.62.
Can you provide the expected EPS growth for RHK stock?
The Earnings per Share (EPS) of RHOEN-KLINIKUM AG (RHK.DE) is expected to grow by 9.14% in the next year.